• Pharmala Biotech entered a term sheet to license exclusive, perpetual U.S. rights to its next-generation MDMA therapeutic ALA-002 to Jupiter Neurosciences in a deal valued at more than USD 100 million, including upfront consideration, milestone payments, and single-digit royalties on net sales.
• Upfront consideration is set at USD 3.33 million at closing of a definitive agreement, including USD 1.5 million in cash and USD 1.83 million in Jupiter common stock, with the shares subject to a 10-day lock-up.
• Jupiter will place USD 600,000 into escrow on signing, credited against the upfront cash payment.
• The parties target closing within 90 days; if no definitive agreement is signed by then, Pharmala would receive the escrowed amount as a reverse termination fee, subject to carve-outs.
• Pharmala will retain rights to ALA-002 outside the U.S., including its existing commercial presence through the Cortexa joint venture in Australia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.